PROM1 and hepatocellular carcinoma: In an attempt to target CD133 therapeutically, Smith et al. used an anti-CD133-antibody (AC133) conjugated to the cytotoxic drug monomethyl auristatin F (MMAF) to effectively target CD133+ HCC cells.